Abstract
This study has investigated the development of antinociceptive tolerance to, and cross-tolerance between, two highly selective delta agonists, [D-Pen2,D-Pen5]enkephalin (DPDPE) and [D-Ala2] deltorphin II as well as to [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAMGO), a highly selective mu agonist, in mice. Intracerebroventricular administration of DPDPE, [D-Ala2]deltorphin II and DAMGO each produced an antinociceptive effect. Pretreatment with i.c.v. DPDPE twice daily for 3 days resulted in tolerance to DPDPE as shown by a 4.8-fold rightward shift in the dose-response curve. In contrast, in DPDPE pretreated mice, the dose-response lines for [D-Ala2]deltorphin II and DAMGO were not altered when compared to those obtained in naive animals. The development of tolerance was also shown by pretreating mice with i.c.v. [D-Ala2]deltorphin II; following this pretreatment, the [D-Ala2Ideltorphin II dose-response line was displaced to the right by more than 37-fold. In contrast, in [D-Ala2]deltorphin II-pretreated mice, the dose-response lines for DPDPE and DAMGO were not altered compared to those obtained in naive animals. Finally, pretreatment with i.c.v. DAMGO produced a rightward displacement of the DAMGO dose-response line of 47-fold, indicating the development of antinociceptive tolerance. In DAMGO-pretreated mice, however, the dose-response lines for DPDPE and [D-Ala2]deltorphin II were not altered compared to those obtained in naive mice. Thus, the data indicate that antinociceptive tolerance develops to DPDPE, [D-Ala2]deltorphin II and DAMGO but that there is no cross-tolerance between these compounds. Although the lack of cross-tolerance between DAMGO and the two delta agonists is not surprising, the additional lack of cross-tolerance between DPDPE and [D-Ala2]deltorphin II suggests possible differences in their mechanism of action. As both DPDPE and [D-Ala2]deltorphin II are highly selective delta agonists which have been shown to elicit antinociception via interactions with a delta receptor, this lack of cross-tolerance suggests that these compounds produce antinociception via interaction with subtypes of delta receptors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 583-587 |
| Number of pages | 5 |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Volume | 258 |
| Issue number | 2 |
| State | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin ii in mice : Evidence for delta receptor subtypes. / Mattia, A.; Vanderah, Todd W; Mosberg, H. I.; Porreca, Frank.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 258, No. 2, 1991, p. 583-587.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Lack of antinociceptive cross-tolerance between [D-Pen2, D-Pen5]enkephalin and [D-Ala2]deltorphin ii in mice
T2 - Evidence for delta receptor subtypes
AU - Mattia, A.
AU - Vanderah, Todd W
AU - Mosberg, H. I.
AU - Porreca, Frank
PY - 1991
Y1 - 1991
N2 - This study has investigated the development of antinociceptive tolerance to, and cross-tolerance between, two highly selective delta agonists, [D-Pen2,D-Pen5]enkephalin (DPDPE) and [D-Ala2] deltorphin II as well as to [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAMGO), a highly selective mu agonist, in mice. Intracerebroventricular administration of DPDPE, [D-Ala2]deltorphin II and DAMGO each produced an antinociceptive effect. Pretreatment with i.c.v. DPDPE twice daily for 3 days resulted in tolerance to DPDPE as shown by a 4.8-fold rightward shift in the dose-response curve. In contrast, in DPDPE pretreated mice, the dose-response lines for [D-Ala2]deltorphin II and DAMGO were not altered when compared to those obtained in naive animals. The development of tolerance was also shown by pretreating mice with i.c.v. [D-Ala2]deltorphin II; following this pretreatment, the [D-Ala2Ideltorphin II dose-response line was displaced to the right by more than 37-fold. In contrast, in [D-Ala2]deltorphin II-pretreated mice, the dose-response lines for DPDPE and DAMGO were not altered compared to those obtained in naive animals. Finally, pretreatment with i.c.v. DAMGO produced a rightward displacement of the DAMGO dose-response line of 47-fold, indicating the development of antinociceptive tolerance. In DAMGO-pretreated mice, however, the dose-response lines for DPDPE and [D-Ala2]deltorphin II were not altered compared to those obtained in naive mice. Thus, the data indicate that antinociceptive tolerance develops to DPDPE, [D-Ala2]deltorphin II and DAMGO but that there is no cross-tolerance between these compounds. Although the lack of cross-tolerance between DAMGO and the two delta agonists is not surprising, the additional lack of cross-tolerance between DPDPE and [D-Ala2]deltorphin II suggests possible differences in their mechanism of action. As both DPDPE and [D-Ala2]deltorphin II are highly selective delta agonists which have been shown to elicit antinociception via interactions with a delta receptor, this lack of cross-tolerance suggests that these compounds produce antinociception via interaction with subtypes of delta receptors.
AB - This study has investigated the development of antinociceptive tolerance to, and cross-tolerance between, two highly selective delta agonists, [D-Pen2,D-Pen5]enkephalin (DPDPE) and [D-Ala2] deltorphin II as well as to [D-Ala2,NMePhe4,Gly-ol5]enkephalin (DAMGO), a highly selective mu agonist, in mice. Intracerebroventricular administration of DPDPE, [D-Ala2]deltorphin II and DAMGO each produced an antinociceptive effect. Pretreatment with i.c.v. DPDPE twice daily for 3 days resulted in tolerance to DPDPE as shown by a 4.8-fold rightward shift in the dose-response curve. In contrast, in DPDPE pretreated mice, the dose-response lines for [D-Ala2]deltorphin II and DAMGO were not altered when compared to those obtained in naive animals. The development of tolerance was also shown by pretreating mice with i.c.v. [D-Ala2]deltorphin II; following this pretreatment, the [D-Ala2Ideltorphin II dose-response line was displaced to the right by more than 37-fold. In contrast, in [D-Ala2]deltorphin II-pretreated mice, the dose-response lines for DPDPE and DAMGO were not altered compared to those obtained in naive animals. Finally, pretreatment with i.c.v. DAMGO produced a rightward displacement of the DAMGO dose-response line of 47-fold, indicating the development of antinociceptive tolerance. In DAMGO-pretreated mice, however, the dose-response lines for DPDPE and [D-Ala2]deltorphin II were not altered compared to those obtained in naive mice. Thus, the data indicate that antinociceptive tolerance develops to DPDPE, [D-Ala2]deltorphin II and DAMGO but that there is no cross-tolerance between these compounds. Although the lack of cross-tolerance between DAMGO and the two delta agonists is not surprising, the additional lack of cross-tolerance between DPDPE and [D-Ala2]deltorphin II suggests possible differences in their mechanism of action. As both DPDPE and [D-Ala2]deltorphin II are highly selective delta agonists which have been shown to elicit antinociception via interactions with a delta receptor, this lack of cross-tolerance suggests that these compounds produce antinociception via interaction with subtypes of delta receptors.
UR - http://www.scopus.com/inward/record.url?scp=0026051553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026051553&partnerID=8YFLogxK
M3 - Article
C2 - 1650835
AN - SCOPUS:0026051553
VL - 258
SP - 583
EP - 587
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
SN - 0022-3565
IS - 2
ER -